TGTX TG Therapeutics Inc.

$12.2 -3.56%

1,194,564 Shares Traded
1,766,104 Average Volume (last 30 days)

as of February 16, 2018 EST IEX Real-Time Price

Short Pain Metrics

Approximate Amount of Money Shorts Have Made on the Day: $8.59 million
If Intiated on the First, Shorts Have Realized a Year to Date Return of:-39.43%
If Intiated One Month Ago, Shorts Have Realized a Return of:-27.75%
If Initiated Five Days ago, Shorts Have Realized a Return of:-2.95%
Peer Potential Short Squeezes Near Real Time Screener
*Please note the actual returns of shorts could be different as they started from different points

Daily Indicators

Daily Short Pain Indicator [i] - Always Use Fundamentals on EverythingNeutral
200 Day Moving Average Indicator Bullish
50 Day Moving Average Indicator Bullish
52 Week High/Low Indicator Neutral

Short Stats

Short Percent to Float 36.21%
Short Interest19.09 million
Float52.73 million
Short Ratio12.27
Market Cap$893.75 million
Market Maker ActivityDaily Short Volume


TG Therapeutics: Further Appreciation In 2018 Likely (SeekingAlpha)
Biotech Forum Daily Digest For February 3rd (SeekingAlpha)
TG Therapeutics' ublituximab continues to show treatment benefit in mid-stage MS study; shares up 10% premarket (SeekingAlpha)
Biotech Forum Daily Digest For January 29th (SeekingAlpha)
2 Small Biotechs With Substantial Upside Potential (SeekingAlpha)
Key events next week - healthcare (SeekingAlpha)
TG Therapeutics (TGTX) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow (SeekingAlpha)
Your Daily Pharma Scoop: Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides Update, Axsome Suffers Setback (SeekingAlpha)
Biotech Forum Daily Digest For Jan. 8th (SeekingAlpha)
Goldman bullish on biopharma in 2018 (SeekingAlpha)

Smart Money Sentiment

Institutional Ownership (Top 15 Funds) 49.5%

Earnings Stats

PE Ratio -6.32
Dividend Yield 0%
Peer EarningsEarnings Calendar


200 Day Moving Average $10.48
50 Day Moving Average $9.85
52 Week High $15.35
52 Week Low $4.5

Data provided for free by IEX. Questions? Read the FAQ